BiotechTube
Home/InflaRx/Jan Medina, CFA
JM

Jan Medina, CFA

Vice President, Head of Investor Relations

InflaRx

Therapeutic Areas

Inflammatory DiseasesCritical CareImmunology

InflaRx Pipeline

DrugIndicationPhase
Vilobelimab (GOHIBIC)Critical COVID-19 (SARS-CoV-2-induced ARDS)Marketed (EUA)
VilobelimabPyoderma GangrenosumPhase 3
Izicopan (IFX-4)Inflammatory DiseasesPreclinical
IFX002Inflammatory DiseasesPreclinical

Leadership Team at InflaRx

PD
Prof. Dr. Niels C. Riedemann
Chief Executive Officer and Founder
PR
Prof. Renfeng Guo, M.D.
Chief Scientific Officer and Founder
DT
Dr. Thomas Taapken
Chief Financial Officer
CC
Camilla Chong, M.D.
Chief Medical Officer
DO
Derval O’Carroll
Senior Vice President, Global Head of Regulatory Affairs & Compliance
DI
Dr. Igor Orshanskiy
Senior Director, Head of Business Development
NF
Nicolas Fulpius
Chairman of the Board
View full InflaRx profile